ClinicalTrials.gg
CompletedNCT00334802Updated Mar 16, 2010Results posted

Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer

A Phase 2 interventional study of gemcitabine and paclitaxel in Metastatic Breast Cancer, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2010-03-16.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Non-randomized
Ages
20 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
49th of 90
62 · median 68
Started
2006
with 7 others
Phase 2
65 of 95
none open now
Registered
43rd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 49th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2006, is one of 65 in phase 2, and was the 43rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

To investigate efficacy, safety and PK of gemcitabine and paclitaxel combination in patients with metastatic breast cancer after adjuvant/neo-adjuvant chemotherapy with anthracycline regimen

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and/or cytologically confirmed breast cancer
  • Received /neo-adjuvant chemotherapy for breast cancer with anthracycline regimen
  • To have at least one measurable region
  • (ECOG) Performance Status: 0-1
  • To have adequate organ function (bone marrow, liver and renal function)

Exclusion criteria

Exclusion Criteria:

  • To have interstitial pneumonia or pulmonary fibrosis
  • To have inflammatory breast cancer
  • Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery
  • To have with symptoms
  • To have severe complication (cardiac infarction, infection, drug or diabetes)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    A

    Drug: gemcitabine · Drug: paclitaxel

Interventions

  • Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation) Phase 2: dose determined by phase 1

    Also known as: LY188011, Gemzar

  • Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles

06

What researchers measure

Primary outcomes

  1. Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.

    Time frame: baseline to measured progressive disease

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

    Time frame: time of response to progressive disease

  2. Time to Progressive Disease

    Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

    Time frame: baseline to measured progressive disease

  3. Number of Participants Alive at One Year (1-Year Survival)

    Time frame: baseline to date of death from any cause, evaluated at 1 year

  4. Pharmacokinetics - Maximum Plasma Concentration (Cmax)

    Maximum plasma concentration of gemcitabine plus paclitaxel on Day 1, Cycle 1, and gemcitabine monotherapy on Day 8, Cycle 1.

    Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)

  5. Pharmacokinetics - Area Under the Concentration Curve (AUC)

    Area under the concentration curve from time zero to infinity.

    Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)

  6. Pharmacokinetics - Half Life (t½)

    Apparent elimination half-life.

    Time frame: cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)

07

Results

Posted Jul 20, 2009

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2
Started656
Completed016
Not completed640
Withdrew: Progressive disease224
Withdrew: Toxicity15
Withdrew: Lack of efficacy13
Withdrew: Patient condition aggrevated10
Withdrew: Physician decision10
Withdrew: Withdrawal by subject04
Withdrew: Adverse event03
Withdrew: Criteria for starting next cycle not met01

Outcome measures

PrimaryTumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Responders are patients with complete response or partial response.

Time frame:
baseline to measured progressive disease
Reported as:
Number · participants
Tumor Response
participantsDose Level 1Dose Level 2
Complete Response00
Partial Response325
Stable Disease117
Progressive Disease111
Not Evaluable13
Statistical analysis
  • Dose Level 1 · t-test, 2 sided · p = 0.169 (P-value for Dose Level 1 Responders (Complete Response + Partial Response))
  • Dose Level 2 · t-test, 2 sided · p = 0.001 (P-value for Dose Level 2 Responders (Complete Response + Partial Response))
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.

Time frame:
time of response to progressive disease
Reported as:
Median · months
Duration of Response
monthsDose Level 2
Duration of Response4.70 (1.2 to 7.3)
SecondaryTime to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.

Time frame:
baseline to measured progressive disease
Reported as:
Median · days
Time to Progressive Disease
daysDose Level 1Dose Level 2
Time to Progressive Disease310.5 (42 to 455)194.0 (29 to 265)
SecondaryNumber of Participants Alive at One Year (1-Year Survival)
Time frame:
baseline to date of death from any cause, evaluated at 1 year
Reported as:
Number · participants
Number of Participants Alive at One Year (1-Year Survival)
participantsDose Level 1Dose Level 2
Number of Participants Alive at One Year (1-Year Survival)545
SecondaryPharmacokinetics - Maximum Plasma Concentration (Cmax)

Maximum plasma concentration of gemcitabine plus paclitaxel on Day 1, Cycle 1, and gemcitabine monotherapy on Day 8, Cycle 1.

Time frame:
cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics - Maximum Plasma Concentration (Cmax)
nanograms per milliliter (ng/mL)Gemcitabine + PaclitaxcelGemcitabine
Pharmacokinetics - Maximum Plasma Concentration (Cmax)25800 (12800 to 43600)25400 (20000 to 33100)
SecondaryPharmacokinetics - Area Under the Concentration Curve (AUC)

Area under the concentration curve from time zero to infinity.

Time frame:
cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*hr/mL)
Pharmacokinetics - Area Under the Concentration Curve (AUC)
nanograms*hour per milliliter (ng*hr/mL)Gemcitabine + PaclitaxcelGemcitabine
Pharmacokinetics - Area Under the Concentration Curve (AUC)16300 (11700 to 25500)14700 (11500 to 21000)
SecondaryPharmacokinetics - Half Life (t½)

Apparent elimination half-life.

Time frame:
cycle 1, day 1 (0 minutes, 3, 3.25, 3.5, 3.58, 3.75, 4, 4.5, 5 hours) and 8 (0, 15, 30, 35, 45, 60, 90, 120 minutes)
Reported as:
Geometric mean · hours
Pharmacokinetics - Half Life (t½)
hoursGemcitabine + PaclitaxcelGemcitabine
Pharmacokinetics - Half Life (t½)0.282 (0.192 to 1.00)0.258 (0.162 to 0.969)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1———
Dose Level 2———
Most frequent serious events
Most frequent serious events
EventDose Level 1Dose Level 2
Haemoglobin decreasedInvestigations1/60/56
PneumoniaInfections and infestations0/61/56
AnorexiaMetabolism and nutrition disorders0/61/56
Panic disorderPsychiatric disorders0/61/56
Most frequent other events
Showing 10 of 205
Most frequent other events
EventDose Level 1Dose Level 2
Alanine amiontransferase increasedInvestigations6/644/56
Haemoglobin decreasedInvestigations6/642/56
Neutrophil count decreasedInvestigations4/654/56
White blood cell count decreasedInvestigations5/652/56
MalaiseGeneral disorders5/634/56
Platelet count decreasedInvestigations4/639/56
Aspartate aminotransferase increasedInvestigations4/638/56
AlopeciaSkin and subcutaneous tissue disorders4/634/56
Lymphocyte count decreasedInvestigations4/628/56
Blood alkaline phosphatase increasedInvestigations4/614/56

Baseline characteristics

Age Continuous
Age Continuous(years)Dose Level 1Dose Level 2Total
Mean58.2 ± 4.4954.4 ± 8.7354.7 ± 8.46
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Total
Female65662
Male000
Region of Enrollment
Region of Enrollment(participants)Dose Level 1Dose Level 2Total
Japan65662
Age at Primary Diagnosis
Age at Primary Diagnosis(participants)Dose Level 1Dose Level 2Total
<30 years old000
30 to <40 years old033
40 to <50 years old12021
50 to <60 years old32427
60 to <70 years old2810
≥70 years old011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Dose Level 1Dose Level 2Total
0 - Fully Active45054
1 - Ambulatory, Restricted Strenuous Activity268
Body Weight
Body Weight(kilograms)Dose Level 1Dose Level 2Total
Mean57.18 ± 15.31355.76 ± 8.71555.90 ± 9.375
Height
Height(centimeters)Dose Level 1Dose Level 2Total
Mean153.53 ± 7.987154.71 ± 6.184154.60 ± 6.312
08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 464-8681, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 296-8602, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, 790-0007, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 814-0180, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, 373-8550, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 737-0023, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 060-0006, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Iwate, 020-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima, 892-0833, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 259-1193, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 862-8505, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 590-0064, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 338-8553, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shizuoka, 430-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 104-8560, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Feb 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2006
First posted
Jun 8, 2006
Start
Jun 2006
Primary completionActual
Feb 2008
CompletionActual
Mar 2010
Results first posted
Jul 20, 2009
Last update
Mar 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00334802
First posted
Jun 8, 2006
Start date
Jun 2006
Primary completion
Feb 2008
Completion
Mar 2010
Results posted
Jul 20, 2009
Last update
Mar 16, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Paclitaxel

Start the discussion